|Bid||64.50 x 400|
|Ask||64.53 x 2400|
|Day's Range||64.31 - 64.75|
|52 Week Range||63.88 - 88.85|
|PE Ratio (TTM)||6.82|
|Dividend & Yield||2.08 (3.22%)|
|1y Target Est||N/A|
Gilead Sciences’ (GILD) tenofovir alafenamide fumarate (or TAF) based regimens have seen high adoption rates in the US and European markets.
The Financial Women of San Francisco selected Gilead Sciences Chief Financial Officer Robin Washington as its 2017 Financial Woman of the Year. Washington was also recognized this week as the recipient of the lifetime achievement award at the “2017 Bay Area CFO of the Year Awards,” a program conducted by Larkin Street Youth Services in partnership with the Business Times. In accepting her award this week, it was clear that Washington spent a good portion of her career staying one step ahead of Oracle’s M&A department.
In 1Q17, Gilead Sciences’ (GILD) Genvoya generated revenues of around $769 million. The drug has seen double-digit sequential sales growth in every quarter since its launch in November 2015.